Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 41,308 |
|
|||||
| News | - | ||||||
| Day High | 6.565 | Low High |
|||||
| Day Low | 6.28 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ESSA Pharma Inc | EPIX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.32 | -4.87% | 6.25 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.47 | 6.28 | 6.565 | 6.25 | 6.57 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 787 | 41,308 | $ 6.44 | $ 266,094 | - | 2.56 - 11.67 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 1,198 | $ 6.25 | USD |
ESSA Pharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 282.24M | 44.24M | - | 0 | -26.58M | -0.60 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ESSA Pharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EPIX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.46 | 7.59 | 6.18 | 6.50 | 83,656 | -1.21 | -16.22% |
| 1 Month | 8.94 | 9.19 | 6.18 | 7.65 | 66,384 | -2.69 | -30.09% |
| 3 Months | 8.59 | 11.67 | 6.18 | 9.33 | 128,304 | -2.34 | -27.24% |
| 6 Months | 3.82 | 11.67 | 3.80 | 7.69 | 131,188 | 2.43 | 63.61% |
| 1 Year | 2.77 | 11.67 | 2.56 | 6.06 | 107,047 | 3.48 | 125.63% |
| 3 Years | 27.13 | 36.00 | 1.40 | 6.51 | 490,088 | -20.88 | -76.96% |
| 5 Years | 2.35 | 36.00 | 1.40 | 7.63 | 334,233 | 3.90 | 165.96% |
ESSA Pharma Description
| ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. |
